A New Paradigm in Treatment of Brain Metastases
Anectodal reports of clinical improvement in patients with brain metastases following “well placed, moderate X-ray therapy” were reported as early as 1931, supporting the role of even primitive radiation techniques in palliation of patients with brain metastases 1. In this era prior to computed tomography (CT) and magnetic resonance imaging (MRI), patients with brain metastases presented with significant clinical symptoms. “Hemiplegia and incontinence are usually present by the time the patient is referred to the radiotherapist, and many have fits and papilledema” reported the first critical assessment of whole bra...
Source: Current Problems in Cancer - March 26, 2015 Category: Cancer & Oncology Authors: Mark W. McDonald, Kevin P. McMullen Source Type: research
Neurosurgical Management of Brain Metastases
Management of brain metastases continues to evolve. Neurosurgical considerations when evaluating patients with brain metastases include the size, location, and number of lesions as well as the primary cancer type, systemic disease burden, and preoperative functional state. Oncologic treatment advances continue to lengthen the overall survival of these patients thereby increasing the incidence of patients ultimately requiring intervention for their intracranial disease. We review current evidence and emerging surgical technologies that are changing the decision making landscape for neuro-oncologists. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - March 26, 2015 Category: Cancer & Oncology Authors: Analiz Rodriguez, Stephen B. Tatter Source Type: research
Diagnostic Imaging of Intracranial Metastasis
Intracranial metastases are the most common intracranial neoplasms in adults with an incidence of 20-40% of adult patients with cancer 1,2. Although there is potential for nearly any malignancy to metastasize to the brain, the most common tumors to metastasize to the brain in order of decreasing frequency are lung, breast, melanoma, colorectal, and kidney 1. Intracranial metastases are most frequently diagnosed in patients with an established primary site of malignancy. To a lesser extent, brain metastases may be the initial presentation of an occult malignancy in ≤ 30% of patients 3. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - March 26, 2015 Category: Cancer & Oncology Authors: Stephen F. Kralik, Aaron P. Kamer, Chang Y. Ho Source Type: research
Title Page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - March 1, 2015 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - March 1, 2015 Category: Cancer & Oncology Source Type: research
Author BioSketch
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - March 1, 2015 Category: Cancer & Oncology Source Type: research
Erratum to “Surgery in malignant bone tumors” [Current Problems in Cancer 2013;37(4):192-197]
In the print version of this article, there was a misspelling of the author “Yale A. Fillingham.” The author׳s surname should have been spelt as “Fillingham” instead of “Filingham.” (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - March 1, 2015 Category: Cancer & Oncology Authors: Steven Gitelis, Christopher O. Bayne, Jonathan M. Frank, Yale A. Fillingham, Paul M. Kent Source Type: research
Title Page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2015 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2015 Category: Cancer & Oncology Source Type: research
Author BioSketch
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2015 Category: Cancer & Oncology Source Type: research
Epidemiology of advanced prostate Cancer: Overview of known and less Explored Disparities in prostate Cancer prognosis
Several studies have investigated potential explanations of the well-known disparate survival of African-Americans with prostate cancer compared to Caucasian patients in the United States. Using data from the Detroit SEER registry for the period 1988-1992. Schwartz and colleagues found that African-American men with localized/regional prostate cancer had a 30% lower survival than their white counterparts. The corresponding difference in survival for those with distant disease was 75% 1. These disparities in all cause-mortality were explained by socioeconomic status (SES) and treatment, but not by the differences in age and...
Source: Current Problems in Cancer - November 26, 2014 Category: Cancer & Oncology Authors: Lauren E. Holz, Michael Goodman Source Type: research
The biology of castration-resistant prostate cancer
Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men in the United States.1 Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy (ADT)2 is the standard of care once a patient has recurrent disease following primary surgical or radiation therapy; however, the benefits from ADT are typically short lived. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Fei Lian, Nitya V. Sharma, Josue D. Moran, Carlos S. Moreno Source Type: research
The Biology of Castrate Resistant Prostate Cancer
Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death for males in the United States1. Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy (ADT)2 is the standard of care once a patient has recurrent disease following primary surgical or radiation therapy; however, the benefits from ADT are typically short-lived. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Fei Lian, Nitya Sharma, Josue D. Moran, Carlos S. Moreno Source Type: research
Molecular Imaging of Advanced Prostate Cancer
Advanced prostate cancer presents a diagnostic challenge to clinicians. Though prostate cancer prevalence may be declining it still remains the second highest cause of cancer death1. The treatment of prostate cancer in advanced stages requires significant intervention including surgery, chemotherapy, radiotherapy and supportive care, and remains a major public health problem. Earlier detection and identification of advanced prostate cancer is a diagnostic dilemma. In this summary we will review the current status and future direction of molecular imaging for advanced prostate cancer. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Peter J. Rossi, David M. Schuster Source Type: research
Surgery for High-Risk Prostate Cancer and Metastatic Prostate Cancer
Prostate cancer is the highest incidence solid organ cancer observed in men and the number two oncologic killer of men worldwide1. High-risk prostate cancer, per the American Urological Association (AUA) guidelines, is defined as PSA equal to or greater than 20 ng/mL, clinical stage equal to or greater than T2c, and/or Gleason score equal to or greater than 82. The European Association of Urology (EAU), as well as the National Comprehensive Cancer Network (NCCN), have a similar definition with one exception: high-risk clinic stage is T3a or higher3. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Ilan J. Safir, Fei Lian, Mehrdad Alemozaffar, Viraj A. Master Source Type: research
